Johnson & Johnson Launches "Dual Control" Campaign in Asia Pacific to Empower Patients with IBD to Balance Disease Management ...

Japan had 254.8 cases of ulcerative colitis and 77 cases of Crohn's per 100,000 people, and a new study shows that the cases ...

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European ...

The 28-year-old defender is now supporting IBD research by the Royal Devon University Healthcare NHS Foundation Trust and the ...

"It affected everything. It made being a dad so difficult - especially as my children are both younger than four." ...

Ustekinumab is effective and safe and shows a high rate of clinical remission and treatment persistence in patients with ulcerative colitis.

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...

The FDA has expanded the approval of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC) to include an SC induction regimen.

Over 300,000 Canadians live with chronic inflammatory bowel diseases (IBD), including Crohn's and ulcerative colitis.

This month, the company received FDA approval for a subcutaneous induction regimen of Tremfya (guselkumab) to treat adults ...

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European ...